Pharmaceutical composition for the treatment of neurodegenerative disease

Abstract

A pharmaceutical composition for neurodegenerative disease and stem cell therapy includes Salviae miltiorrhizae radix et rhizoma, Angelicae sinensis radix, Astragali Radix, Artemisiae Argyi Folium, Anoectochilus formosanus, Anisomeles Indica, and Cordyceps militaris. Besides, this invention also provides a uses and products of the pharmaceutical composition.

Description

[Technical Field]

[0001] This invention relates to a pharmaceutical composition, and more particularly to a pharmaceutical composition for treating neurodegenerative diseases. [Previous Technology]

[0002] As the global population ages, the incidence of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, has increased significantly, becoming one of the major health problems affecting the elderly. The main characteristics of these diseases include neuronal damage or death, leading to symptoms such as memory loss, cognitive decline, and behavioral abnormalities. Currently, clinical treatment for these diseases mainly relies on chemotherapy to alleviate symptoms, but these drugs often have side effects or are toxic to other healthy cells.

[0003] Therefore, researchers in related fields have begun to focus on developing the medicinal value of natural substances such as herbs. Many herbs, due to their antioxidant, anti-inflammatory, and neuroprotective properties, are increasingly being applied to research related to neurodegenerative diseases. For example, extracts of Ginkgo biloba have been shown to improve blood circulation and memory function, while curcumin, contained in Curcuma longa, has antioxidant and anti-inflammatory effects. In recent years, various herbal compound combinations have been put into use to treat neurodegenerative diseases. For example, the National Institutes of Health's Neuropsychiatric Research Center has proposed a traditional Chinese medicine compound, PM012, extracted from Rehmannia glutinosa, Dioscorea opposita, Cornus officinalis, Poria cocos, Alisma plantago-aquatica, Paeonia suffruticosa, and Lycium barbarum, to enhance the expression of neurotrophic factor (BDNF) in nerve cells, reduce the area of ​​cerebral infarction, and thus improve memory impairment.

[0004] However, existing herbal compound combinations usually need to fully consider the synergistic effect of each component in the compound combination to ensure the stability and uniformity of the activity of each material. Therefore, there is still room for improvement in its application in clinical medicine. [Summary of the Invention]

[0005] Therefore, the object of the present invention is to provide a pharmaceutical composition for the treatment of neurodegenerative diseases and stem cell therapy, which not only produces therapeutic effects on neurodegenerative diseases, but also reduces side effects and ensures the stability of therapeutic effects.

[0006] The present invention provides a pharmaceutical composition for the treatment of neurodegenerative diseases and stem cells, comprising: one danshen (Salvia miltiorrhiza), one angelica sinensis (Angelica sinensis), one astragalus membranaceus (Astragalus membranaceus), one mugwort leaf (Artemisia argyi), one Anoectochilus roxburghii (Anoectochilus roxburghii), one senna plantago-aquatica (Anoectochilus roxburghii), and one Cordyceps sinensis fruiting body.

[0007] Preferably, the pharmaceutical composition comprises: 2 to 3 parts by weight of the danshen, 2 to 3 parts by weight of the angelica, 2 to 3 parts by weight of the astragalus, 5 to 6 parts by weight of the mugwort, 2.5 to 3.5 parts by weight of the anoectochilus roxburghii, 5.5 to 6.5 parts by weight of the clematis, and 5 to 6 parts by weight of the fruiting body of Cordyceps militaris.

[0008] Preferably, the content of Anoectochilus roxburghii is between 8 wt% and 14 wt% based on the total weight of the pharmaceutical composition.

[0009] Another object of the present invention is to provide the application of a pharmaceutical composition for the treatment of neurodegenerative diseases and stem cell therapy.

[0010] The present invention relates to the application of a pharmaceutical composition for the treatment of neurodegenerative diseases and stem cell therapy, using the pharmaceutical composition as described above. The pharmaceutical composition is in the form of tablets, powder, or solution.

[0011] Another object of the present invention is to provide a pharmaceutical structure for the treatment of neurodegenerative diseases and stem cells, using the pharmaceutical composition as described above.

[0012] The present invention provides a pharmaceutical structure for the treatment of neurodegenerative diseases and stem cell therapy, comprising a body and the pharmaceutical composition.

[0013] The body defines a containment space in which the pharmaceutical composition is in the form of a powder or solution and is placed.

[0014] The efficacy of this invention lies in the following: the pharmaceutical composition has a good therapeutic effect on nerve cells with neurodegenerative diseases, while exhibiting low toxicity to healthy nerve cells, thus reducing the side effects of the pharmaceutical composition on the human body. Furthermore, the pharmaceutical composition can also be used to regulate the human biological clock, effectively preventing healthy nerve cells from developing neurodegenerative diseases due to biological clock disruption. In addition, the pharmaceutical composition and stem cells can produce a synergistic effect, making the therapeutic effect on neurodegenerative diseases of nerve cells even better. Furthermore, the pharmaceutical composition also has a therapeutic effect on stem cells, preventing them from losing cell activity under aging conditions, and further increasing the protein content of their survival proteins, longevity genes, and self-renewal genes, promoting the functional enhancement of stem cells.

Implementation Method

[0015] The technical content and effects of the present invention will be clearly presented in conjunction with the drawings and the following detailed description of the embodiments. It should be noted that the drawings of the present invention are only used to illustrate the relative positional relationship between the components and are not related to the actual size of each component.

[0016] An embodiment of the present invention is a pharmaceutical composition for the treatment of neurodegenerative diseases and stem cell therapy, the pharmaceutical composition being used for the treatment of neurodegenerative diseases (e.g., memory loss or Parkinson's disease) and / or stem cell therapy.

[0017] According to the present invention, the pharmaceutical composition may be in the form of tablets, powders, or solutions, depending on the intended use. When the pharmaceutical composition is a solution, it may be obtained by extraction of the raw materials of the pharmaceutical composition. In some embodiments, the pharmaceutical composition may also be applied to serum. In other embodiments, the pharmaceutical composition may also be used for the purpose of in vitro culture of stem cells.

[0018] Furthermore, the pharmaceutical composition can also be used to formulate a pharmaceutical structure comprising a body 10 defining a receiving space 13, and the pharmaceutical composition contained in the receiving space 13, the pharmaceutical composition being in the form of a powder or a solution. The pharmaceutical structure can be as shown in FIG8, where the body 10 is a capsule composed of a first shell 11 and a second shell 12 joined together; or as shown in FIG9, where the body 10 is a water-permeable packaging material.

[0019] In this embodiment, the pharmaceutical composition comprises: Salviae miltiorrhizae radix et rhizoma, Angelicae sinensis radix, Astragalus membranaceus Radix, Artemisiae Argyi Folium, Anoectochilus formosanus, Anisomeles indica, and Cordyceps militaris. The Anisomeles indica is the same as the one mentioned above.

[0020] In this embodiment, the weight parts of the danshen are 2 to 3, the weight parts of the angelica are 2 to 3, the weight parts of the astragalus are 2 to 3, the weight parts of the mugwort are 5 to 6, the weight parts of the golden thread orchid are 2.5 to 3.5, the weight parts of the moxa are 5.5 to 6.5, and the weight parts of the golden cordyceps fruiting body are 5 to 6. Wherein, based on the total weight of the pharmaceutical composition, the content of the golden thread orchid is between 8 wt% and 14 wt%.

[0021] Preferably, the weight parts of the ginseng are 2.5, the weight parts of the angelica are 2.5, the weight parts of the astragalus are 2.5, the weight parts of the mugwort are 5.5, the weight parts of the golden thread orchid are 3, the weight parts of the moxa are 6, and the weight parts of the golden cordyceps fruiting body are 5.5.

[0022] Preferably, the content of the golden orchid is between 9 wt% and 11 wt%.

[0023] In detail, the pharmaceutical composition has advantages such as anti-aging, improving memory and low toxicity to human cells, and has a therapeutic effect on nerve cells in the human body that exhibit neurodegenerative diseases, and helps maintain the cell activity of the nerve cells themselves.

[0024] Because the pharmaceutical composition itself contains plant stem cells and exosomes, it also has the effect of enhancing stem cell stability and helping to repair aging stem cells. Furthermore, the pharmaceutical composition helps to promote the multipotential differentiation potential of stem cells, enabling them to promote cell proliferation and prolong cell lifespan under specific conditions.

[0025] On the other hand, stem cells themselves have a repairing effect on nerve cells because they have functions such as secreting nerve growth factors and helping to repair cells. Therefore, when this pharmaceutical composition is used to produce a therapeutic effect on the stem cells, the pharmaceutical composition and the stem cells treated by the pharmaceutical composition can also jointly produce a therapeutic effect on nerve cells. Compared with the repair effect of the stem cells themselves, the therapeutic effect on the cell activity of nerve cells is more advantageous due to the synergistic effect produced by the pharmaceutical composition and the stem cells treated by the pharmaceutical composition.

[0026] The medical use of the aforementioned pharmaceutical composition in nerve cells and / or stem cells will be further described, and the following experiment will be conducted on a formulation solution prepared from the pharmaceutical composition.

[0027] The formulation solution is obtained by dissolving the pharmaceutical composition in sterile water and filtering it through a 0.45 μM pore size filter membrane to remove excess impurities and bacteria. The pharmaceutical composition contains 2.5 parts by weight of Salvia miltiorrhiza, 2.5 parts by weight of Angelica sinensis, 2.5 parts by weight of Astragalus membranaceus, 5.5 parts by weight of Artemisia argyi, 3 parts by weight of Anoectochilus roxburghii, 6 parts by weight of Clematis chinensis, and 5.5 parts by weight of Cordyceps militaris fruiting body.

[0028] First Experiment

[0029] This first experiment is a therapeutic use test for a neurodegenerative disease, used to examine the medical use of the pharmaceutical composition on nerve cells, with Parkinson's disease as an example. The first experiment includes the following steps:

[0030] First, a differentiation step is performed to prepare 9 groups of nerve cells with the same condition parameters, wherein the nerve cells are SHSY5Y; the 9 groups of nerve cells are induced to differentiate into dopamine cells (i.e., dopamine neurons) using retinoic acid (RA), and the differentiation reaction time is 24 hours; next, a toxin induction step is performed to expose the dopamine cells to a neurotoxin (concentration of 50 μM) for induction, so that the dopamine cells are induced to become toxin-induced cells, thereby simulating the state of nerve cell degeneration in Parkinson's disease. The reaction time of this step is 24 hours, wherein the neurotoxin is 6-hydroxydopamine (6-OHDA); finally, a treatment step is performed to add 9 different concentrations of formulation solutions to the 9 groups of toxin-induced cells to perform a treatment reaction, so as to obtain 9 groups of first detection nerve cells a1~a9, and the treatment reaction time is 24 hours. The concentrations of the formulation solutions used to obtain the first detection nerve cells a1 to a9 are shown in Table 1.

[0031] A cell viability test was performed on the first detection nerve cells a1-a9. The cell viability of the nine groups of first detection nerve cells a1-a9, their corresponding reference cells, and a comparative example a0 was detected, and the results were shown in the bar chart in Figure 1. The nine groups of reference cells were obtained by adding the corresponding concentration of the formulation solution to nerve cells with the same parameters and performing the treatment step. The comparative example a0 was a nerve cell without the addition of the formulation solution. The parameters of the nine groups of first detection nerve cells a1-a9 and the comparative example a0 are summarized in Table 1.

[0032] A protein property test was performed on one group of first detection nerve cells a7. The protein expression levels of the nerve cells, the toxin-induced cells, and the first detection cells a7 obtained during the first experiment were measured and observed. The protein property test was performed using Western blot analysis, and the resulting image is shown in Figure 2.

[0033] Table 1 nerve cells Toxin-induced cells First detection of nerve cells Reference cells Formulation solution concentration (ug / ml) Comparative example a0 SHSY5Y SHSY5Y / 6-OHDA SHSY5Y / 6-OHDA-Formulation SHSY5Y - Formula 0 a1 1 a2 10 a3 20 a4 50 a5 100 a6 150 a7 200 a8 250 a9 300

[0034] Referring to Figures 1, 2A, and 2B, Figure 1 shows that the cell activity of the reference cells (SHSY5Y-formulation) indicates that the pharmaceutical composition has no significant or low toxicity to nerve cells. Therefore, when this pharmaceutical composition is used for treatment, it will not cause side effects to patients or damage other healthy cells. Furthermore, the cell activity of the first-tested nerve cells a4-a9 shows that after reacting with a formulation solution at a sufficient concentration (i.e., the concentration of the pharmaceutical composition is higher than 20 ug / ml), the cell activity of the first-tested nerve cells a4-a9 significantly increased, and their activity was even higher than that of the untreated comparative example a0. Therefore, this pharmaceutical composition has an extremely good therapeutic effect on nerve cells exhibiting a state of nerve cell degeneration.

[0035] As shown in Figure 2A, compared to the nerve cell and the toxin-induced cell, the expression levels of α-synuclein and c-PARP in the proteins of the first-detection nerve cell a7 decreased. This means that the condition of Parkinson's disease caused by cell apoptosis due to synuclein accumulation can be improved under the treatment of this medical composition. Furthermore, compared to the nerve cell and the toxin-induced cell, the inflammatory factor (IL-β) in the first-detection nerve cell a7 decreased, while the neurotrophic factor (BDNF) increased, indicating that the pharmaceutical composition also has anti-inflammatory, repairing, and nerve-nourishing effects. As shown in Figure 2B, compared with the nerve cell and the toxin-induced cell, the longevity gene (SIRT1) of the first tested nerve cell a7 was increased, and the circadian rhythm genes (CLOCK, PER2) were also changed. It can be seen that the pharmaceutical composition has the effect of prolonging the life of nerve cells in a state of nerve cell degeneration and can regulate the patient's circadian rhythm, avoiding the occurrence of Parkinson's disease due to circadian rhythm disorder.

[0036] Second Experiment

[0037] This second experiment is a therapeutic use test for a neurodegenerative disease, used to examine the medical use of the pharmaceutical composition in combination with nerve cells and stem cells. The second experiment includes the following steps:

[0038] First, five groups of nerve cells (SHSY5Y) with identical condition parameters were prepared for the differentiation step; next, the toxin induction step was performed using five different concentrations of neurotoxin (6-OHDA); then, the treatment step was performed using a formulation solution with a concentration of 200 ug / ml for 6 hours to obtain five groups of pre-treated nerve cells; finally, a stem cell treatment step was performed, adding stem cells to each group of pre-treated nerve cells and allowing a 24-hour reaction to obtain five groups of second-detection nerve cells b1~b5 in the second experimental example. The stem cells were adipose-derived stem cells (ADSC).

[0039] Cell activity tests were performed on the second detection nerve cells b1-b5, their corresponding pre-treatment nerve cells, toxin-induced cells, a reference cell, and a set of comparative examples b0, resulting in the bar graph shown in Figure 3. The parameter conditions of the five groups of second detection nerve cells b1-b5 and the comparative example b0 are summarized in Table 2. The reference cells in each group were obtained by directly reacting the toxin-induced cells with stem cells without adding the formulation solution.

[0040] Table 2 Toxin-induced cells Pretreatment of nerve cells Second detection of nerve cells Reference cells Neurotoxin concentration (μM) Comparative example b0 SHSY5Y / 6-OHDA SHSY5Y - Formula SHSY5Y - Formula / coADSC SHSY5Y / coADSC 0 b1 SHSY5Y / 6-OHDA-Formulation SHSY5Y / 6-OHDA-Formulation / coADSC SHSY5Y / 6-OHDA / coADSC 10 b2 20 b3 30 b4 50 b5 60

[0041] Referring to Figure 3, in comparative example b0, stem cells did not show a significant therapeutic effect on nerve cells without neurodegenerative diseases. However, from the cell activity performance of the second-tested nerve cells b2-b5, and their corresponding reference cells and pre-treated cells, it can be seen that using stem cells alone or the pharmaceutical composition can enhance cell activity and produce a therapeutic effect on nerve cells with neurodegenerative diseases. Specifically, the cell activity of the second-tested nerve cells b2-b5 was higher than that of their corresponding reference cells and pre-treated cells. In other words, compared to using stem cells or the pharmaceutical composition alone, the combination of stem cells and the pharmaceutical composition has a better therapeutic effect on neurodegenerative diseases.

[0042] Third Experiment

[0043] This third experiment is a stem cell therapeutic use test to examine the medical use of the pharmaceutical composition for the combination of nerve cells and stem cells. The third experiment includes the following steps:

[0044] First, a stem cell (ADSC) was added to a nerve cell (SHSY5Y), and the differentiation step was performed on the nerve cell; then, the toxin induction step was performed with the neurotoxin (6-OHDA) at a concentration of 50 μM; then, a formulation solution at a concentration of 200 ug / ml was added to perform the treatment step, and the treatment time was 6 hours, resulting in a third detection nerve cell and a third detection stem cell.

[0045] The third detection stem cell and the stem cells obtained in each step were subjected to the protein property detection to measure the protein expression level of the stem cell after reacting with the nerve cell (SHSY5Y), the toxin-induced cell (SHSY5Y / 6-OHDA) and the third detection nerve cell (SHSY5Y / 6-OHDA-formulation), respectively, and the images were obtained as shown in Figure 4A and Figure 4B.

[0046] Referring to Figures 4A and 4B, compared with the stem cells that react with the nerve cells and toxin-induced cell responses, the third detection stem cells that react with the pharmaceutical composition showed a significant increase in neural precursor cell protein (CD133), self-renewal protein (Oct4, Nanog), longevity gene (SIRT1), and survival protein (IGF1-R, p-Akt). This indicates that the pharmaceutical composition also has a good therapeutic effect on the stem cells and can also improve their cell lifespan, self-renewal, and survival capabilities.

[0047] Fourth Experiment

[0048] This fourth experiment is a neurotherapy use test to examine the medical use of the pharmaceutical composition for the combination of neural cells and stem cells. This fourth experiment includes the following steps:

[0049] First, four groups of stem cells (ADSCs) with identical condition parameters were used. Two groups were added to a nerve cell line (SHSY5Y), and the other two groups were added to a toxin-induced cell line (SHSY5Y / 6-OHDA). A biofilm was placed on the culture dish containing these stem cells. The toxin-induced cells were obtained in the same manner as in the first experiment. Next, a formulation solution with a concentration of 200 ug / ml was added to one group of nerve cells and toxin-induced cells, and a formulation solution with a concentration of 100 ug / ml was added to another group of nerve cells and toxin-induced cells to perform the treatment step. The treatment time was 6 hours. Finally, the cells were allowed to stand for 8 hours to observe the migration performance of each group of stem cells on their respective biofilms (c1-c4). A comparative example (c0) was used for comparison, resulting in the image shown in Figure 5. The comparative example (c0) shows the migration performance of the two groups of stem cells in relation to the nerve cells and toxin-induced cells without the formulation solution. Migration behaviors c1 and c2 represent the response of the stem cells to the calls made by the nerve cells with formulation solutions containing different concentrations of 100 ug / ml and 200 ug / ml, respectively; migration behaviors c3 and c4 represent the response of the stem cells to the calls made by the toxin-induced cells with formulation solutions containing different concentrations of 100 ug / ml and 200 ug / ml, respectively.

[0050] As shown in Figure 5, compared with comparative example c0, the migration performance of the stem cells c1-c4 was enhanced under the action of the pharmaceutical composition, and showed a positive relationship with the concentration of the pharmaceutical composition. This indicates that the pharmaceutical composition can also promote the therapeutic effect of the stem cells on nerve cells. Furthermore, the migration performance of the stem cells c3 and c4 was more active than that of c1 and c2. This shows that compared with healthy nerve cells, the stem cells have a better therapeutic effect on nerve cells with neurodegenerative disease (i.e., toxin-induced cells), and produce a synergistic effect with the therapeutic effect of the pharmaceutical composition.

[0051] Fifth Experiment

[0052] This fifth experiment is a therapeutic use test for stem cell aging, used to examine the medical use of the pharmaceutical composition for stem cell aging. This fifth experiment includes the following steps:

[0053] First, a first formulation solution with a concentration of 100 mg / kg and a second formulation solution with a concentration of 300 mg / kg were prepared. The first formulation solution and the second formulation solution were respectively fed to a young experimental mouse (8 weeks old) and an old experimental mouse (18 months old), and left to rest for 2 hours. During the aforementioned process, serum Y (before feeding), serum YL (after feeding with the first formulation solution), and serum YH (after feeding with the second formulation solution) were obtained from the young experimental mouse, and serum O, serum OL (after feeding with the first formulation solution), and serum OH (after feeding with the second formulation solution) were obtained from the old experimental mouse. Afterwards, Eight groups of stem cells (ADSCs) with identical parameters were prepared. Two groups of stem cells were cultured as comparative examples d0-1 and d0-2 without the addition of any serum. The other six groups of stem cells were cultured with serum Y, serum YO, serum YO, serum O, serum OL, and serum OH, respectively. During the culture process, except for comparative example d0-1, the other seven groups of stem cells were induced to age with galactose (D-galactose) at a concentration of 10 g / L to obtain the fifth detection stem cells.

[0054] The fifth detection stem cells d1-d4, obtained by culturing with serum Y, serum O, serum OL, and serum OH, and the stem cells of comparative examples d0-01 and d0-2 were subjected to the cell viability test, and the results are shown in Figure 6. The protein properties of the fifth detection stem cells d3 and d4 and the stem cells of comparative examples d0-01 and d0-2 were tested, and the results are shown in Figure 7.

[0055] Table 3 stem cells Induced aging D-galactose serum Formulation solution concentration (mg / kg) Comparative example d0-1 ADSC x - - Comparative example d0-2 o - - d1 o Y 0 d2 o O 0 d3 o OL 100 d4 o OH 300

[0056] Referring to Figures 6 and 7, as shown in Figure 6, compared with the aging stem cells of Comparative Example d0-2, the serum Y obtained from the young experimental mouse has a protective effect on the galactose-induced aging stem cells, and the aging-induced stem cells (i.e., the five-detection stem cells d1) maintain cell activity better than those of Comparative Example d0-2, thereby delaying the aging process. The serum O obtained from the older experimental mouse has a poor protective effect on the aging-induced stem cells (i.e., the five-detection stem cells d2). When the older experimental mouse was given a formulation solution prepared with different concentrations of the pharmaceutical composition, the serum O1 and O2 obtained significantly improved the cell activity of the aging-induced stem cells (i.e., the five-detection stem cells d3 and d4), and its protective effect was no less than that of the serum Y obtained from the young experimental mouse, and even better. Moreover, the effect of improving cell activity is positively correlated with the concentration of the pharmaceutical composition contained in the formulation solution. Clearly, this pharmaceutical composition has both protective and therapeutic effects on stem cells, effectively preventing their aging. Therefore, when aging individuals use this composition, they can indeed enhance their ability to protect and delay stem cell aging, achieving an anti-aging capacity comparable to or even better than that of younger individuals. Furthermore, applying this composition to serum also has a therapeutic effect on stem cells.

[0057] As shown in Figure 7, compared with the aging stem cells of Comparative Example d0-2, under the combined action of serum OL and OH containing the components of the pharmaceutical composition, the self-renewal proteins (Oct4, Nanog), longevity genes (SIRT1), and survival proteins (p-Akt) of the five tested stem cells d3 and d4 were significantly increased in the aging environment. It can be seen that the pharmaceutical composition not only has a good therapeutic effect on the stem cells, but also improves their cell lifespan, self-renewal and survival capabilities.

[0058] In summary, the pharmaceutical composition of the present invention for the treatment of neurodegenerative diseases and stem cells has a good therapeutic effect on nerve cells with neurodegenerative diseases and low toxicity to healthy nerve cells. At the same time, it can effectively reduce the accumulation of toxic cells, inflammatory factors and apoptosis proteins. Therefore, the side effects of the pharmaceutical composition on the human body are very low. Furthermore, the pharmaceutical composition can also regulate the physiological clock genes and longevity genes of the nerve cells, which can effectively prevent healthy nerve cells from developing neurodegenerative diseases. Moreover, the pharmaceutical composition and the stem cells can also produce a synergistic effect, making the therapeutic effect on neurodegenerative diseases of nerve cells even better. In addition, the pharmaceutical composition also has a therapeutic effect on stem cells, which can prevent them from losing cell activity under aging environment and further increase the protein content of their survival proteins, longevity genes and self-renewal genes, and promote the functional improvement of stem cells. Therefore, it can indeed achieve the purpose of the present invention. [Simplified Explanation of the Diagram]

[0059] Figure 1 is a bar graph illustrating the relationship between cell activity and concentration of a first detection nerve cell obtained in a first experiment using the pharmaceutical composition of the present invention for the treatment of neurodegenerative diseases and stem cell therapy; Figures 2A and 2B are images illustrating the protein expression levels of the first detection nerve cell; Figure 3 is a bar graph illustrating the relationship between cell activity and concentration of a second detection nerve cell obtained in a second experiment using the pharmaceutical composition; Figures 4A and 4B are images illustrating the protein expression levels of a first detection stem cell obtained in a third experiment using the pharmaceutical composition; Figure 5 is a staining image of a biological membrane illustrating the cell migration behavior of stem cells obtained in a fourth experiment using the pharmaceutical composition; Figure 6 is a bar graph illustrating the relationship between cell activity and concentration of a fifth detection stem cell obtained in a fifth experiment using an example of the pharmaceutical composition; Figure 7 is an image illustrating the protein expression levels of the fifth detection stem cell; and Figures 8 and 9 are schematic diagrams illustrating different embodiments of the pharmaceutical structure of the present invention for the treatment of neurodegenerative diseases and stem cell therapy.

Claims

1. A pharmaceutical composition for treating dopamine neurodegenerative diseases, comprising: a stem cell; and a formulation solution, wherein the formulation solution comprises extracts of Salviae miltiorrhizae radix et rhizoma, Angelicae sinensis radix, Astragalus membranaceus, Artemisiae Argyi Folium, Anoectochilus formosanus, Anisomeles indica, and Cordyceps militaris, wherein... The steps for treating dopamine neurodegenerative diseases include: pretreating a degenerative dopamine nerve with the formulated solution to obtain a pretreated nerve cell; and adding the stem cell to each group of pretreated nerve cells.

2. The pharmaceutical composition as claimed in claim 1, wherein, In this formulation solution, the weight parts of Salvia miltiorrhiza are 2 to 3, the weight parts of Angelica sinensis are 2 to 3, the weight parts of Astragalus membranaceus are 2 to 3, the weight parts of Artemisia argyi are 5 to 6, the weight parts of Anoectochilus roxburghii are 2.5 to 3.5, the weight parts of Cordyceps militaris are 5.5 to 6.5, and the weight parts of Cordyceps sinensis fruiting bodies are 5 to 6.

3. The pharmaceutical composition as claimed in claim 1, wherein, The content of *Anoectochilus roxburghii* is between 8 wt% and 14 wt% based on the total weight of the pharmaceutical composition.

4. The use of a pharmaceutical composition in the preparation of a treatment for dopamine neurodegenerative diseases, comprising the pharmaceutical composition as described in any one of claims 1 to 3, wherein, The pharmaceutical composition is in the form of tablets, powder, or solution.

5. A pharmaceutical structure for treating dopamine neurodegenerative diseases, comprising: a body defining a receiving space; and a pharmaceutical composition as described in any one of claims 1 to 3, in the form of a powder or a solution, disposed in the receiving space.

6. The pharmaceutical structure as described in claim 5, wherein, The main body is a capsule.

Images